Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study With Open-label Extension, to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects With Recurrent Pericarditis

Trial Profile

Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study With Open-label Extension, to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects With Recurrent Pericarditis

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rilonacept (Primary)
  • Indications Pericarditis
  • Focus Registrational; Therapeutic Use
  • Acronyms RHAPSODY
  • Sponsors Kiniksa Pharmaceuticals
  • Most Recent Events

    • 20 Nov 2019 According to a Kiniksa Pharmaceuticals media release, The Clinical Endpoint Committee will adjudicate all suspected pericarditis recurrences for inclusion in the primary efficacy endpoint analysis.
    • 07 Mar 2019 According to a Kiniksa Pharmaceuticals media release, top-line data from this study are expected in the second half of 2020.
    • 11 Dec 2018 According to a Kiniksa Pharmaceuticals media release, Dr. Allan Klein of Cleveland Clinic and Dr. Massimo Imazi of the University of Torino, Italy, are the co-principal investigator of this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top